Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).
Noam E. Kopmar(University of Washington), Ryan D. Cassaday(University of Washington), Jason P. Cooper(University of Washington), Erik L. Kimble(University of Washington), Jonathan R. Fromm(University of Iowa), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cristina Maria Ghiuzeli(University of Washington), Joshua Veatch(University of Washington), Mary‐Elizabeth M. Percival(Fred Hutch Cancer Center), Ted Gooley(Fred Hutch Cancer Center), Raya Mawad(Fred Hutch Cancer Center), Christen H. Martino(University of Washington), Ashtyn Sherrow(Fred Hutch Cancer Center), Paul C. Hendrie(University of Washington), Noah Pinke(Fred Hutch Cancer Center), Johnnie J. Orozco(Fred Hutch Cancer Center)
Cited by 0
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441